Applied DNA Sciences 将来の成長

Future 基準チェック /16

Applied DNA Sciencesの収益は年間4.9%で減少すると予測されていますが、年間収益は年間18.5%で増加すると予想されています。EPS は年間127%で増加すると予想されています。

主要情報

-4.9%

収益成長率

127.0%

EPS成長率

Life Sciences 収益成長	26.2%
収益成長率	18.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	25 Jun 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:UDJ - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2025	7	-13	N/A	N/A	2
9/30/2024	4	-13	N/A	N/A	2
3/31/2024	6	-13	-12	-11	N/A
12/31/2023	9	-7	-9	-8	N/A
9/30/2023	13	-10	-7	-6	N/A
6/30/2023	16	-7	-7	-7	N/A
3/31/2023	18	-5	-8	-7	N/A
12/31/2022	19	-7	-8	-8	N/A
9/30/2022	18	-8	-9	-9	N/A
6/30/2022	18	-12	-12	-10	N/A
3/31/2022	15	-15	-12	-10	N/A
12/31/2021	12	-14	-15	-13	N/A
9/30/2021	9	-14	-16	-13	N/A
6/30/2021	6	-14	-14	-12	N/A
3/31/2021	5	-14	-16	-13	N/A
12/31/2020	3	-15	-14	-13	N/A
9/30/2020	2	-13	-12	-11	N/A
6/30/2020	3	-10	-10	-10	N/A
3/31/2020	5	-9	-8	-8	N/A
12/31/2019	5	-8	-8	-8	N/A
9/30/2019	5	-9	-7	-7	N/A
6/30/2019	5	-11	-8	-8	N/A
3/31/2019	4	-12	-8	-7	N/A
12/31/2018	4	-12	-6	-6	N/A
9/30/2018	4	-12	-7	-7	N/A
6/30/2018	4	-11	-6	-5	N/A
3/31/2018	5	-11	-6	-6	N/A
12/31/2017	4	-12	N/A	-8	N/A
9/30/2017	5	-13	N/A	-7	N/A
6/30/2017	5	-12	N/A	-9	N/A
3/31/2017	4	-13	N/A	-9	N/A
12/31/2016	4	-13	N/A	-9	N/A
9/30/2016	4	-12	N/A	-10	N/A
6/30/2016	7	-10	N/A	-9	N/A
3/31/2016	8	-9	N/A	-8	N/A
12/31/2015	9	-7	N/A	-7	N/A
9/30/2015	9	-12	N/A	-7	N/A
6/30/2015	6	-13	N/A	-7	N/A
3/31/2015	4	-14	N/A	-8	N/A
12/31/2014	3	-15	N/A	-9	N/A
9/30/2014	3	-13	N/A	-9	N/A
6/30/2014	3	-15	N/A	-8	N/A
3/31/2014	3	-15	N/A	-8	N/A
12/31/2013	2	-15	N/A	-8	N/A
9/30/2013	2	-18	N/A	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: UDJ今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: UDJ今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: UDJ今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: UDJの収益 ( 18.5% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: UDJの収益 ( 18.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: UDJの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Applied DNA Sciences 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Forecast to breakeven in 2023

Applied DNA Provides Revenue Guidance for the Fiscal Second Quarter Ended March 31, 2021

Recent updates

Applied DNA Sciences, Inc. Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Applied DNA Sciences, Inc. announced that it has received funding

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.499893 million.

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc.'s Applied DNA Clinical Labs, LLC Launches Mpox Clade I and Clade II Testing Service

Applied DNA Sciences, Inc. to Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Applied DNA Sciences, Inc. to Report Q3, 2024 Results on Aug 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Sep 30, 2024

Applied DNA Sciences Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Applied DNA Sciences, Inc. Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million.

Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million.

Applied DNA Sciences, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering.

Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress

First quarter 2024 earnings released: US$0.075 loss per share (vs US$0.30 loss in 1Q 2023)

New major risk - Shareholder dilution

Applied DNA Sciences, Inc. to Report Q1, 2024 Results on Feb 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.436992 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.437233 million.

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$0.76 loss per share (vs US$0.93 loss in FY 2022)

Applied DNA Sciences Receives Non-Compliance Notice From Nasdaq

Applied DNA Sciences, Inc. to Report Q4, 2023 Results on Dec 07, 2023

Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna)

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.13 loss in 3Q 2022)

Applied DNA Sciences, Inc. to Report Q3, 2023 Results on Aug 10, 2023

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

Applied DNA Sciences, Inc. (NasdaqCM:APDN) acquired Spindle Biotech Inc. for $2.8 million.

New major risk - Share price stability

Second quarter 2023 earnings released: EPS: US$0.046 (vs US$0.23 loss in 2Q 2022)

Applied DNA Sciences, Inc. to Report Q2, 2023 Results on May 11, 2023

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.63 loss in 1Q 2022)

Applied DNA Sciences, Inc. to Report Q1, 2023 Results on Feb 09, 2023

Applied DNA Sciences, Inc. Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA as New Class of DNA-Based Vaccines

Full year 2022 earnings released: US$0.93 loss per share (vs US$2.07 loss in FY 2021)

Insufficient new directors

Applied DNA Sciences, Inc. to Report Q4, 2022 Results on Dec 05, 2022

Applied DNA Sciences, Inc.'s Subsidiary, Applied DNA Clinical Labs, LLC, Launches Monkeypox Testing Service

Applied DNA Submits PCR-Based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.46 loss in 3Q 2021)

Applied DNA Sciences, Inc. Announces Retirement of John Bitzer from Board of Directors

Applied DNA Sciences, Inc. Launches Initiatives to Expand Awareness of LinearDNA Platform as Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website

Applied DNA and Evvivax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA Platform

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in 2Q 2021)

Applied DNA Sciences, Inc. to Report Q2, 2022 Results on May 12, 2022

Applied DNA Sciences, Inc. and EvviVax, S.R.L. Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Applied DNA Sciences, Inc. to Report Q1, 2022 Results on Feb 10, 2022

Applied DNA Sciences, Inc. to Deploy Linea™ 1.0 COVID-19 Assay for Rapid Detection of New Omicron Subvariant BA.2

Applied DNA Clinical Labs Receives New York State Department of Health Conditional Approval for Linea™ 2.0 COVID-19 Assay as Laboratory Developed Test

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

No longer forecast to breakeven

Forecast to breakeven in 2023

Third quarter 2021 earnings released: US$0.46 loss per share (vs US$0.72 loss in 3Q 2020)

Applied DNA Sciences and A&E Introduce Anti-Counterfeiting Technology for Sustainable Sewing Threads

Applied DNA Sciences, Inc. and Evvivax, S.R.L. Announce Results from in Vitro Neutralization Study of Sera

Applied DNA Completes Technical Validation of PCR-based SARS-CoV-2 Mutation-Detection Panel, Highlights Ability to Rapidly Identify Mutations and Probable Variants

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.79 loss in 2Q 2020)

Applied Dna Sciences, Inc. Clarifies the Scope of Its Newly Authorized Asymptomatic Serial Screening Indication for Its Linea Covid-19 Assay Kit

FDA Grants EUA to Applied DNA LineaTM COVID-19 Assay Kit for Asymptomatic Screening of Individuals with Serial Testing

Applied DNA Receives CLIA Certification, Enabling High Throughput Diagnostic Covid-19 Testing

Applied DNA and Evvivax Announce LinearDNA™ COVID-19 Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines

Applied DNA Provides Revenue Guidance for the Fiscal Second Quarter Ended March 31, 2021

Applied DNA Sciences, Inc. Receives Blanket Purchase Order for Linea™ COVID-19 Assay Kits for 10,000 Tests